Hui Quan
Sanofi (France) · 132 works · 10,213 citations · h-index 32
Top works
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
- A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
- Effects of Specific Inhibition of Cyclooxygenase-2 on Sodium Balance, Hemodynamics, and Vasoactive Eicosanoids
- Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
- Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine
- Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet
- Studies of the oral bioavailability of alendronate*
- A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas
- Some statistical methods for multiple endpoints in clinical trials
- Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis
- Specific inhibition of cyclooxygenase‐2 with MK‐0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
- Assessing Reproducibility by the Within-Subject Coefficient of Variation with Random Effects Models
- TESTING FOR TREATMENT DIFFERENCES WITH DROPOUTS PRESENT IN CLINICAL TRIALS - A COMPOSITE APPROACH
- Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial
- Peptic Ulcer and Bleeding Events Associated With Rofecoxib in a 3-Year Colorectal Adenoma Chemoprevention Trial
- A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects
- Sample size considerations for Japanese patients in a multi‐regional trial based on MHLW guidance
- The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events